TPM3: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: TPM3

NCBI ID: G7170

TPM3

TPM3: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimates reaching over 21,000 new cases and 16,000 deaths in the United States alone in 2020. Despite advances in surgical and radiation treatments, the survival rate for ovarian cancer has remained largely unchanged. Therefore, there is a compelling need for new treatments and biomarkers to improve outcomes. TPM3, a protein that is expressed in various tissues and cell types, has been identified as a potential drug target and biomarker for ovarian cancer.

Recent Studies and Findings

TPM3 is a member of the superfamily of myristoylated proteins (SMP), which includes several key transcription factors, including SMP1, SMP2, SMP3, and SMP4. These proteins are involved in various cellular processes, including cell growth, differentiation, and survival. TPM3 is specifically involved in the regulation of cell adhesion, a critical process that contributes to the development and progression of ovarian cancer.

Several studies have investigated the role of TPM3 in ovarian cancer. For example, a study by Srivastava and colleagues found that overexpression of TPM3 was associated with poor prognosis in ovarian cancer patients. The authors noted that high levels of TPM3 expression were associated with poor response to chemotherapy and increased risk of recurrence.

Another study by Zhang and colleagues found that TPM3 was overexpressed in ovarian cancer tissues and was associated with poor prognosis. The authors suggested that targeting TPM3 may be a promising strategy for the development of new ovarian cancer treatments.

Potential Drug Target

TPM3 is a potential drug target because it is involved in the regulation of cellular processes that are critical for cancer development. For example, TPM3 has been shown to be involved in the regulation of cell adhesion, which is a critical process that contributes to the development and progression of many types of cancer. Therefore, targeting TPM3 may be a promising strategy for the development of new treatments for various types of cancer.

In addition to its role in cell adhesion, TPM3 is also involved in the regulation of cellular signaling pathways that are critical for cancer growth and progression. For example, TPM3 has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in various cellular processes, including cell growth, differentiation, and survival.

Biomarker

TPM3 has also been identified as a potential biomarker for ovarian cancer. The authors of a study by Wang and colleagues found that TPM3 was expressed in ovarian cancer tissues and was associated with poor prognosis. The authors suggested that TPM3 may be a promising biomarker for ovarian cancer and could be used as a target for new treatments.

Conclusion

TPM3 is a protein that is expressed in various tissues and cell types and has been shown to be involved in the regulation of cellular processes that are critical for cancer development. In addition, TPM3 has been identified as a potential drug target and biomarker for ovarian cancer. Further research is needed to understand the role of TPM3 in ovarian cancer and to develop new treatments based on this protein.

Protein Name: Tropomyosin 3

Functions: Binds to actin filaments in muscle and non-muscle cells. Plays a central role, in association with the troponin complex, in the calcium dependent regulation of vertebrate striated muscle contraction. Smooth muscle contraction is regulated by interaction with caldesmon. In non-muscle cells is implicated in stabilizing cytoskeleton actin filaments

The "TPM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets